 |
|
 |
Therapeutic |
|
|
Inflammatory Disease Therapeutics
Pipelines and Competitive Dynamics
Publication Date June 2005
Publisher Cambridge Healthtech Advisors
Product Type Report
Pages 166
ISBN Number not applicable
Product Code CHA016
|
|
|
Summary
Inflammatory Disease Therapeutics: Pipelines and Competitive Dynamics comprehensively evaluates R&D efforts for six high-profile immune/inflammatory disorders:
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Psoriasis
• Lupus
• Multiple Sclerosis
• Asthma
The complexity of the immune system provides both opportunity and challenge for those in the pharmaceutical industry trying to manipulate it. There is a seemingly endless list of cytokines, receptors, and enzymes that can be disrupted in patients with autoimmune and inflammatory diseases, and the sheer number of options leaves plenty of chances for large established players and specialized newcomers alike to carve out niches for themselves.
However, the transition from brainstorm to marketed drug is fraught with pitfalls. Targeting a single receptor or protein often means being foiled by the immune system’s redundancy, while cutting too wide a swath through the system can result in unexpected side effects. Despite Herculean efforts to develop newer and better agents for treating these conditions, frustratingly few novel drugs have passed muster in clinical trials and reached the market in the last decade. The market continues to eagerly await safe and effective alternatives to existing therapies.
Inflammatory Disease Therapeutics examines the mechanisms of immune/inflammatory disease, reviews the existing drug therapies for each of the six diseases covered, and surveys some of drug development attempts that have failed in the last several years.
The report then analyzes the range of new pharmacologic approaches being explored for treating inflammatory disorders, focusing on 14 pharma/biotech company pipelines for each of the six diseases individually. New therapies to treat inflammatory diseases are evaluated using SWOT analysis to compare emerging compounds with standard therapies. These include an analysis of Bristol-Myers Squibb’s abatacept, the next novel rheumatoid arthritis treatment likely to be approved; a comparison of adhesion molecule blockers with standard inflammatory bowel disease therapy; and an evaluation of MBP peptide vaccines for multiple sclerosis therapy, an approach that could arrest the disease process rather than merely treating symptoms.
|
Content
Chapter 1. Introduction: The Immune System and the Inflammatory Response
1.1. The Immune System
1.2. Immune Dysfunction and Autoimmune Disease
Chapter 2. Review of Inflammatory Diseases: Epidemiology, Pathology, Diagnosis, and Symptoms
2.1. Rheumatoid Arthritis (RA)
Pathology of RA
Causes of RA
Diagnosis of RA
Epidemiology of RA
2.2. Inflammatory Bowel Disease (IBD)
Pathology of IBD
Causes of IBD
Diagnosis of IBD
Epidemiology of IBD
2.3. Psoriasis
Pathology of Psoriasis
Causes of Psoriasis
Diagnosis of Psoriasis
Epidemiology of Psoriasis
2.4. Lupus
Pathology of Lupus
Causes of Lupus
Diagnosis of Lupus
Epidemiology of Lupus
2.5. Multiple Sclerosis (MS)
Pathology of MS
Causes of MS
Diagnosis of MS
Epidemiology of MS
2.6. Asthma
Pathology of Asthma
Causes of Asthma
Diagnosis of Asthma
Epidemiology of Asthma
Chapter 3. Current Pharmacologic Treatment Options
3.1. Rheumatoid Arthritis
Analgesics and NSAIDs
Corticosteroids
Synthetic DMARDs
-Methotrexate
-Arava (leflunomide)
-Other DMARDs
Biologic DMARDs
-Enbrel (etanercept)
-Remicade (infliximab)
-Humira (adalimumab)
-Kineret (anakinra)
3.2. Inflammatory Bowel Disease
Aminosalicylates
Corticosteroids
Immunomodulators
-Azathioprine and 6-mercaptopurine
-Methotrexate
-Cyclosporine
-Remicade (infliximab)
Antibiotics
3.3. Psoriasis
Topical Therapies
-Corticosteroids
-Vitamin D3 and A Analogs
-Coal Tar
-Anthralin
-Salicylic Acid
Light Therapy
Systemic Therapy
-Methotrexate
-Cyclosporine
-Oral Retinoids
-Hydroxyurea
-Amevive (alefacept)
-Raptiva (efalizumab)
-Enbrel (etanercept)
3.4. Lupus
NSAIDs
Antimalarials
Corticosteroids
Immunomodulators
3.5. Multiple Sclerosis
Corticosteroids
Disease-Modifying Agents
-Interferon ß
-Copaxone (glatiramer acetate)
-Novantrone (mitoxantrone)
-Tysabri (natalizumab)
Other Immunomodulators
3.6. Asthma
Quick-Relief Medications
-Bronchodilators
-Oral Corticosteroids
Long-Term Control Medications
-Inhaled Corticosteroids
-Bronchodilators
-Mast Cell Stabilizers
-Leukotriene Modifiers
-Xolair (omalizumab)
Chapter 4. Compounds in Development: The Next Generation of Drugs for Inflammatory Diseases
4.1. New Approaches to Inflammatory Diseases
Cytokine Inhibitors
Anti-Inflammatory Cytokines
Compounds Targeting T-Cell Antigens
CD20-Targeted Monoclonal Antibodies
Complement Inhibitors
Adhesion Molecule Blockers
Chemokine Receptor Antagonists
Protease Inhibitors
-TACE
-ICE
-Cathepsin S
Kinase Inhibitors
-p38 MAP Kinase
-JNK
-NF-kB
PPAR-y Ligands
4.2. Setbacks
4.3. Rheumatoid Arthritis
Cytokine Inhibitors
-Regeneron Pharmaceuticals
-Targeted Genetics
-Domantis/Peptech
-Fulcrum Pharmaceuticals
-Nastech Pharmaceutical
Compounds Targeting T-Cell Antigens
-Bristol-Myers Squibb
Complement Inhibitors
-Alexion Pharmaceuticals
Kinase Inhibitors
-Rigel Pharmaceuticals
-Plexxikon/Phenomix
4.4. Inflammatory Bowel Disease
Cytokine Inhibitors
-Abbott Laboratories
-Protein Design Labs
Anti-Inflammatory Cytokines
-Berlex Laboratories
Compounds Targeting T-Cell Antigens
-Protein Design Labs
Adhesion Molecule Blockers
-Isis Pharmaceuticals
-Millennium Pharmaceuticals
Kinase Inhibitors
-Serono/InDex Pharmaceuticals
4.5. Psoriasis
Cytokine Inhibitors
-Isotechnika
-CombinatoRx
Compounds Targeting T-Cell Antigens
-TolerRx
Growth Factor Inhibitors
-Antisense Therapeutics; Isis Pharmaceuticals
Immunomodulators
-Biogen Idec/Fumapharm
Vitamin D Analogs
-QuatRx Pharmaceuticals
-Cytochroma
4.6. Lupus
Immunomodulators
-La Jolla Pharmaceutical
-Genelabs Technologies
Cytokine Inhibitors
-Medarex/MedImmune
BLyS Antagonists
-Human Genome Sciences
-ZymoGenetics/Serono
-Amgen
-Biogen Idec/Genentech
Complement Inhibitors
-Elusys Therapeutics
4.7. Multiple Sclerosis
Immunosuppressants
-Genzyme Oncology
-Novartis Pharmaceuticals
Cytokines
-Transition Therapeutics
-Nastech Pharmaceutical
-Serono/Syntonix Pharmaceuticals
-Maxygen
-Biovation
-Nautilus Biotech
-Bolder Biotechnology
-Pepgen
Peptide Vaccines
-Immune Response
-Neurocrine Biosciences
-BioMS Medical
4.8. Asthma
Cytokine Inhibitors
-Protein Design Labs/Roche
-GlaxoSmithKline
-Amgen
-Amrad/Merck
-Cambridge Antibody Technology
-Regeneron Pharmaceuticals
-Isis Pharmaceuticals
-Sirna Therapeutics
-MedImmune/Genaera
Chemokine Receptor Antagonists
-GlaxoSmithKline
-Merck
-AnorMED
-Novartis Pharmaceuticals
-Cambridge Antibody Technology
Phosphodiesterase-4 Inhibitors
-Altana
-Celgene
-Glenmark Pharmaceuticals/Forest Laboratories
-Toll-Like Receptor Agonists
-Dynavax Technologies
-Coley Pharmaceutical Group/Sanofi-Aventis
-Hybridon
-Corixa
Syk Kinase Inhibitors
-Rigel Pharmaceuticals/Pfizer
-sanofi-aventis
Chapter 5. Company Research Programs
5.1. Abbott Laboratories
5.2. Amgen
5.3. Biogen Idec
5.4. Celgene
5.5. ChemoCentryx
5.6. GlaxoSmithKline
5.7. Isis Pharmaceuticals
5.8. Medarex
5.9. Millennium Pharmaceuticals
5.10. Protein Design Labs
5.11. Regeneron Pharmaceuticals
5.12. Rigel Pharmaceuticals
5.13. Serono
5.14. TolerRx
5.15 Vertex Pharmaceuticals
References
Index
|
|
|
